[go: up one dir, main page]

WO2016140629A1 - A topical composition comprising calendula, hypericum and lidocaine - Google Patents

A topical composition comprising calendula, hypericum and lidocaine Download PDF

Info

Publication number
WO2016140629A1
WO2016140629A1 PCT/TR2015/000088 TR2015000088W WO2016140629A1 WO 2016140629 A1 WO2016140629 A1 WO 2016140629A1 TR 2015000088 W TR2015000088 W TR 2015000088W WO 2016140629 A1 WO2016140629 A1 WO 2016140629A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
topical pharmaceutical
composition according
oil
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2015/000088
Other languages
French (fr)
Inventor
Ersin Yildirim
Tolga Ramazan KARASU
Hakan Gürpinar
Mustafa Serkan SOLMAZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmactive Ilac Sanayi Ve Tlcaret A S
Original Assignee
Pharmactive Ilac Sanayi Ve Tlcaret A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmactive Ilac Sanayi Ve Tlcaret A S filed Critical Pharmactive Ilac Sanayi Ve Tlcaret A S
Priority to PCT/TR2015/000088 priority Critical patent/WO2016140629A1/en
Publication of WO2016140629A1 publication Critical patent/WO2016140629A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Definitions

  • the present invention relates to the topical composition
  • the topical composition comprising Calendula officinalis, Hypericum perforatum and a local anesthetic; that can be used for the treatment and the cure of external lesions, which have wound healing, antiseptic, anti-bacterial, anti-inflammatory and pain relieving properties.
  • Calendula or marigold has been used since the time of the Greeks as a skin balm and antiinflammatory.
  • Calendula (Gold-Bloom ) marigold is a genus of about 12-20 species annual or perennial herbaceous plants in the daisy family Asteraceae, native to an area from Macaronesia east through the Mediterranean to Iran. It is commonly used for skin conditions including minor abrasions and burns, conjunctivitis, aphthous stomatitis, pharyngitis, hemorrhoids, diaper rashes and ulcers.
  • marigold has been shown to increase blood circulation and to aid in healing blood stagnation bruises. Experimental in vivo research suggests that marigold gently stimulates the immune system and promotes lymphatic drainage as well as reducing inflammation and pain.
  • St. John's wort or Hypericum has been used to treat many ailments, including cuts, grazes, bruises, minor bums, sciatica, injured nerves, inflammations, ulcers, poisonous reptile bites, kidney and lung ailments, allergic reactions, anxiety and depression.
  • St. John's wort is also a good source of antioxidants: with 11.7% of its content being bioflavonoids such as rutin, hyperoside, quercetin and quercrtrin, St. John's wort is one of the most concentrated herb sources of antioxidants.
  • Local anaesthetic is a type of medication used to numb areas of the body. Local anaesthetic causes a complete loss of pain sensation to a specific area of body without losing consciousness. It works by blocking the nerves from the affected part of body so that signals can't reach the brain. It only takes a few minutes to lose feeling in the area where local anaesthetic is given. Medical uses are acute pain, chronic pain, surgery, podiatry, dentistry, painless venipuncture and some endoscopic procedures such as bronchoscopy (visualization of the lower airways) or cystoscopy (visualization of the inner surface of the bladder). Topical anaesthesia contains local anaesthetic and is available over the counter from pharmacists in the form of creams, sprays and ointments.
  • W01997/42963 describes an ointment used in the treatment of burnings and skin diseases that includes some types of plants such as Chelidonium majus, Plantago major, Matricaria chamomilla, Achillea millefolium, Calendula officinalis, Hypericum perforatum, Eucalyptus globus, Oleum olivarum and yellow beewax of Cera flava.
  • WO2005/063266 describes a composition for topical use that uses the extract of Calendula officinalis and Hypericum perforatum that they include peptides of low molecular weight and free aminoacids. Described composition in this document is destined for the treatment of psoriasis.
  • the problems in treating wound still exist since these drugs available are not sufficient to improve conditions and alleviate symptoms like epithelial damage, stinging, inflamation. There is a need for improvement of the known drugs due to fast and complete healing requisites.
  • the present invention relates to topical application of a safe pharmaceutical composition
  • a safe pharmaceutical composition comprising Calendula officinalis, Hypericum perforatum and a local anesthetic; that can be used for the treatment and the cure of external lesions, which have wound healing, antiseptic, antibacterial, anti-inflammatory and pain relieving properties.
  • topical pharmaceutical composition comprising Calendula officinalis, Hypericum perforatum and a local anesthetic.
  • topical pharmaceutical composition of present invention contains Calendula officinalis which can be used in the form of essential oil or alcoholic or non-alcoholic extract thereof.
  • topical pharmaceutical composition of present invention contains Hypericum perforatum which can be used in the form of essential oil or alcoholic or nonalcoholic extract thereof.
  • Local anesthetics belong to one of two classes: aminoamide and aminoester local anesthetics. Ester class local anesthetics are prone to producing allergic reactions, which may necessitate the use of an amide class.
  • local anesthetics can be selected from the group consisting of Benzocaine, Chloroprocaine, Cyclomethycaine, Dimethocaine, Piperocaine, Propoxycaine, Procaine, Proparacaine, Tetracaine, Articaine, Bupivacaine, Cinchocaine, Etidocaine, Levobupivacaine, Lidocaine, Mepivacaine, Prilocaine, Ropivacaine, Trimecaine and pharmaceutical acceptable salts thereof.
  • local anesthetic is selected from amide class due to safety reasons. More preferably, local anesthetic is lidocain in the form of base or acid addition salts thereof.
  • Lidocaine is a well known and commercially available local anesthetic of amide class. It is widely used to treat pain and itching associated with insect bites, sunburn, contact dermatitis, and in connection with anal-rectal conditions such as hemorrhoids, fissures and infections.
  • the topical anesthetic material is disposed in a carrier which is a cream, lotion or gel, and in many instances, liposomal structures are particularly favored carriers.
  • liposomal structures comprise vesicles having walls formed from a phospholipid or similar material.
  • topical pharmaceutical composition is in the form of external preparations, such as ointments, creams, gels, lotions, liquids, sprays, cataplasmas, tapes, preferably in the form of gel.
  • topical pharmaceutical composition in addition to the herbal active ingredients described above, topical pharmaceutical composition optionally further contains one or more physiologically acceptable carriers, gelling agents, preservatives, emulsifiers, emollients, humectants, dispersants.
  • topical pharmaceutical composition comprises a pharmaceutically acceptable carrier selected from the group consisting of water, alcohol, almond oil, lanolin, ascorbyl palmitate, beeswax, benzyl alcohol, capryl/capramidopropyl betaine, carboxymethylcellulose sodium, castor oil, cetyl alcohol, cocoa butter, xanthan gum corn oil, hydrogenated vegetable oil, cottonseed oil, glycerin, glyceryl oleate, glyceryl stearate, hydroxyethylcellulose; kaolin, lactose, light mineral oil, microcrystalline wax, olive oil, palm oil, paraffin, PEG 12 diiaurate, Peruvian balsam, petrolatum, polyethylene gycol 300, polyethylene wax, propylene glycol, sorbitan sesquioleate, soybean oil, sucrose, starch, stearyl alcohol, wax, white petrolatum and mixtures thereof.
  • a pharmaceutically acceptable carrier selected from the group consisting of water, alcohol, almond oil,
  • topical pharmaceutical composition comprises a pharmaceutically acceptable gelling agent can be selected from the group consisting of acacia, alginic acid, bentonite, carbopols, carbomer 940, carbomer 941, gelatin, carbomer copolymer, aluminum monostearat, dextrin, magnesium aluminum silicate, silicon dioxide, sodium alginate, triethanolamine, polyvinyl alcohol, pectin, methylcellulose, hydroxypropyl cellulose, aqueous thickening agents such as neutral, anioniocationic polymers and mixtures thereof.
  • a pharmaceutically acceptable gelling agent can be selected from the group consisting of acacia, alginic acid, bentonite, carbopols, carbomer 940, carbomer 941, gelatin, carbomer copolymer, aluminum monostearat, dextrin, magnesium aluminum silicate, silicon dioxide, sodium alginate, triethanolamine, polyvinyl alcohol, pectin, methylcellulose, hydroxypropyl
  • topical pharmaceutical composition comprises an emulsifier can be selected from the group consisting of -20, laureth-3, glyceryl stearate, polyethylene glycol, macrogol cetostearyl ether, stearic acid, stearyl alcohol, polysorbate 60, Irish moss, Tween 80, sorbitol monostearate.glycol esters, fatty acids, fatty alcohols, fatty acid glycol esters, fatty esters, fatty ethers, esters of glycerin, esters of propylene glycol, fatty acid esters of polyethylene glycol, fatty acid esters of polypropylene glycol, esters of sorbitol, esters of sorbitan anhydrides, carboxylic acid copolymers, esters and ethers of glucose, ethoxylated ethers, ethoxylated alcohols, alkyl phosphates, polyoxyethylene fatty ether phosphates, fatty acid
  • topical pharmaceutical composition comprises an emollient can be selected from the group consisting of liquid vaseline, paraffinum liquidum, petrolatum, proplylene glycol, fatty acid esters, mineral oil including dimethicone, waxes including white wax, spermacetic wax, squalene, cetearyl alcohol, cetostearyl alcohol, stearyl alcohol, 2-Octyldodecanol, mineral oil USP, light mineral oil NF, liquid paraffin BP, light liquid paraffin BP.candellilla wax, sweet almond oil, apricot oil, emu oil, argan oil, glycerin, coconut oil, grape seed oil, honey, lanolin and mixtures thereof.
  • an emollient can be selected from the group consisting of liquid vaseline, paraffinum liquidum, petrolatum, proplylene glycol, fatty acid esters, mineral oil including dimethicone, waxes including white wax, spermacetic wax, squalene, ceteary
  • topical pharmaceutical composition comprises a preservative, particularly a preservative selected from the list of potassium sorbate, polyhexanide, paraben (methyl, propyl, butyl, isobutyl), phenoxyethanol, propylene glycol, benzoic acid and benzyl alcohol, particularly potassium sorbate.
  • concentration of the preservative is between about 0.005% and about 0.5%, particularly at about 0.1%, at about 0.2%.
  • topical pharmaceutical composition may not contain any paraben.
  • the preservative is potassium sorbate.
  • potassium sorbate is the sole preservative present in the composition.
  • topical pharmaceutical composition comprises humectant selected from the group consisting of sorbitol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, glycerol, mannitol, xylitol, maltitol, glycerol ethylene oxide (EO), propylene oxide (PO) adducts, and combinations thereof.
  • humectant selected from the group consisting of sorbitol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, glycerol, mannitol, xylitol, maltitol, glycerol ethylene oxide (EO), propylene oxide (PO) adducts, and combinations thereof.
  • the herbal topical composition of the invention preferably are made in a gel base.
  • gel base comprises water, glycerine, Sepineo P600 (acetalization product between glucose and 12-hydroxystearyl alcohol - Seppic) and potassium sorbate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the topical composition comprising Calendula officinalis, Hypericum perforatum and a local anesthetic.

Description

A TOPICAL COMPOSITION COMPRISING CALENDULA, HYPERICUM AND LIDOCAINE
DESCRIPTION Field of the Invention
The present invention relates to the topical composition comprising Calendula officinalis, Hypericum perforatum and a local anesthetic; that can be used for the treatment and the cure of external lesions, which have wound healing, antiseptic, anti-bacterial, anti-inflammatory and pain relieving properties.
Background of the Invention
Calendula or marigold has been used since the time of the Greeks as a skin balm and antiinflammatory. Calendula (Gold-Bloom ) marigold, is a genus of about 12-20 species annual or perennial herbaceous plants in the daisy family Asteraceae, native to an area from Macaronesia east through the Mediterranean to Iran. It is commonly used for skin conditions including minor abrasions and burns, conjunctivitis, aphthous stomatitis, pharyngitis, hemorrhoids, diaper rashes and ulcers. In addition, marigold has been shown to increase blood circulation and to aid in healing blood stagnation bruises. Experimental in vivo research suggests that marigold gently stimulates the immune system and promotes lymphatic drainage as well as reducing inflammation and pain.
Calendula ointment Unguentum "Calendula" which contains tincture of calendula (on 70% spirit 1:10)-20 g, vaseline-90 g: [Mashkovskij M. V. "Medicinal Means", Moscow, "Medicine" 1986, vol. 2, p. 2.424] (US 5997876 CI.1, Ln.7-15).
St. John's wort or Hypericum has been used to treat many ailments, including cuts, grazes, bruises, minor bums, sciatica, injured nerves, inflammations, ulcers, poisonous reptile bites, kidney and lung ailments, allergic reactions, anxiety and depression. In addition, St. John's wort is also a good source of antioxidants: with 11.7% of its content being bioflavonoids such as rutin, hyperoside, quercetin and quercrtrin, St. John's wort is one of the most concentrated herb sources of antioxidants.
There is also known "Ointment Kolkhuri", which contains St.John's-wort, the oak bark, haw- thorn, yarrow, yellow melilot, horse-chestnut 0.06-0.065 in equal quantity, nettle 0.10-0.11 , gum- tree extract 0.02, belladonna extract 0.02, vaseline-the rest; [GE 13, Oarsania, V. 15.05.94]. (US 5997876 CI.1, Ln.17-35). This ointment is used as analgetic and antiinflammatory means and is less effective for healing the wounds and burns, as haw-thorn and belladonna arc not characterized by antiinflammatory and regeneration stimulating effect.
Local anaesthetic is a type of medication used to numb areas of the body. Local anaesthetic causes a complete loss of pain sensation to a specific area of body without losing consciousness. It works by blocking the nerves from the affected part of body so that signals can't reach the brain. It only takes a few minutes to lose feeling in the area where local anaesthetic is given. Medical uses are acute pain, chronic pain, surgery, podiatry, dentistry, painless venipuncture and some endoscopic procedures such as bronchoscopy (visualization of the lower airways) or cystoscopy (visualization of the inner surface of the bladder). Topical anaesthesia contains local anaesthetic and is available over the counter from pharmacists in the form of creams, sprays and ointments.
W01997/42963 describes an ointment used in the treatment of burnings and skin diseases that includes some types of plants such as Chelidonium majus, Plantago major, Matricaria chamomilla, Achillea millefolium, Calendula officinalis, Hypericum perforatum, Eucalyptus globus, Oleum olivarum and yellow beewax of Cera flava.
WO2005/063266 describes a composition for topical use that uses the extract of Calendula officinalis and Hypericum perforatum that they include peptides of low molecular weight and free aminoacids. Described composition in this document is destined for the treatment of psoriasis. Despite the lots of known therapeutical compositions, the problems in treating wound, still exist since these drugs available are not sufficient to improve conditions and alleviate symptoms like epithelial damage, stinging, inflamation. There is a need for improvement of the known drugs due to fast and complete healing requisites.
Summary of the Invention
The present invention relates to topical application of a safe pharmaceutical composition comprising Calendula officinalis, Hypericum perforatum and a local anesthetic; that can be used for the treatment and the cure of external lesions, which have wound healing, antiseptic, antibacterial, anti-inflammatory and pain relieving properties.
Disclosure of the Invention
The present invention provides a topical pharmaceutical composition comprising Calendula officinalis, Hypericum perforatum and a local anesthetic. In one embodiment, topical pharmaceutical composition of present invention contains Calendula officinalis which can be used in the form of essential oil or alcoholic or non-alcoholic extract thereof.
In one embodiment, topical pharmaceutical composition of present invention contains Hypericum perforatum which can be used in the form of essential oil or alcoholic or nonalcoholic extract thereof.
Local anesthetics belong to one of two classes: aminoamide and aminoester local anesthetics. Ester class local anesthetics are prone to producing allergic reactions, which may necessitate the use of an amide class.
In one embodiment, in the present invention, local anesthetics can be selected from the group consisting of Benzocaine, Chloroprocaine, Cyclomethycaine, Dimethocaine, Piperocaine, Propoxycaine, Procaine, Proparacaine, Tetracaine, Articaine, Bupivacaine, Cinchocaine, Etidocaine, Levobupivacaine, Lidocaine, Mepivacaine, Prilocaine, Ropivacaine, Trimecaine and pharmaceutical acceptable salts thereof.
In the preferred embodiment, in the present invention, local anesthetic is selected from amide class due to safety reasons. More preferably, local anesthetic is lidocain in the form of base or acid addition salts thereof.
Lidocaine is a well known and commercially available local anesthetic of amide class. It is widely used to treat pain and itching associated with insect bites, sunburn, contact dermatitis, and in connection with anal-rectal conditions such as hemorrhoids, fissures and infections. In one embodiment of present invention, the topical anesthetic material is disposed in a carrier which is a cream, lotion or gel, and in many instances, liposomal structures are particularly favored carriers. As is known in the art, liposomal structures comprise vesicles having walls formed from a phospholipid or similar material.
In certain embodiments of the present invention, topical pharmaceutical composition is in the form of external preparations, such as ointments, creams, gels, lotions, liquids, sprays, cataplasmas, tapes, preferably in the form of gel.
In certain embodiments of the present invention, in addition to the herbal active ingredients described above, topical pharmaceutical composition optionally further contains one or more physiologically acceptable carriers, gelling agents, preservatives, emulsifiers, emollients, humectants, dispersants.
In certain embodiments of the present invention, topical pharmaceutical composition comprises a pharmaceutically acceptable carrier selected from the group consisting of water, alcohol, almond oil, lanolin, ascorbyl palmitate, beeswax, benzyl alcohol, capryl/capramidopropyl betaine, carboxymethylcellulose sodium, castor oil, cetyl alcohol, cocoa butter, xanthan gum corn oil, hydrogenated vegetable oil, cottonseed oil, glycerin, glyceryl oleate, glyceryl stearate, hydroxyethylcellulose; kaolin, lactose, light mineral oil, microcrystalline wax, olive oil, palm oil, paraffin, PEG 12 diiaurate, Peruvian balsam, petrolatum, polyethylene gycol 300, polyethylene wax, propylene glycol, sorbitan sesquioleate, soybean oil, sucrose, starch, stearyl alcohol, wax, white petrolatum and mixtures thereof.
In certain embodiments of the present invention, topical pharmaceutical composition comprises a pharmaceutically acceptable gelling agent can be selected from the group consisting of acacia, alginic acid, bentonite, carbopols, carbomer 940, carbomer 941, gelatin, carbomer copolymer, aluminum monostearat, dextrin, magnesium aluminum silicate, silicon dioxide, sodium alginate, triethanolamine, polyvinyl alcohol, pectin, methylcellulose, hydroxypropyl cellulose, aqueous thickening agents such as neutral, anioniocationic polymers and mixtures thereof.
In certain embodiments of the present invention, topical pharmaceutical composition comprises an emulsifier can be selected from the group consisting of -20, laureth-3, glyceryl stearate, polyethylene glycol, macrogol cetostearyl ether, stearic acid, stearyl alcohol, polysorbate 60, Irish moss, Tween 80, sorbitol monostearate.glycol esters, fatty acids, fatty alcohols, fatty acid glycol esters, fatty esters, fatty ethers, esters of glycerin, esters of propylene glycol, fatty acid esters of polyethylene glycol, fatty acid esters of polypropylene glycol, esters of sorbitol, esters of sorbitan anhydrides, carboxylic acid copolymers, esters and ethers of glucose, ethoxylated ethers, ethoxylated alcohols, alkyl phosphates, polyoxyethylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, polyethylene glycol 20 sorbitan monolaurate (polysorbate 20) , polyethylene glycol 5 soya sterol, steareth-2, steareth-20, steareth-21, ceteareth-20, PPG- 2 methyl glucose ether distearate, ceteth-10, polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanol amine cetyl phosphate, polysorbate 60, glyceryl stearate, PEG-100 stearate, tragacanth gum, 10-30 alkyl acrylate crosspolymers and mixtures thereof.
In certain embodiments of the present invention, topical pharmaceutical composition comprises an emollient can be selected from the group consisting of liquid vaseline, paraffinum liquidum, petrolatum, proplylene glycol, fatty acid esters, mineral oil including dimethicone, waxes including white wax, spermacetic wax, squalene, cetearyl alcohol, cetostearyl alcohol, stearyl alcohol, 2-Octyldodecanol, mineral oil USP, light mineral oil NF, liquid paraffin BP, light liquid paraffin BP.candellilla wax, sweet almond oil, apricot oil, emu oil, argan oil, glycerin, coconut oil, grape seed oil, honey, lanolin and mixtures thereof. In certain embodiments of the present invention, topical pharmaceutical composition comprises a preservative, particularly a preservative selected from the list of potassium sorbate, polyhexanide, paraben (methyl, propyl, butyl, isobutyl), phenoxyethanol, propylene glycol, benzoic acid and benzyl alcohol, particularly potassium sorbate. In particular embodiment, the concentration of the preservative is between about 0.005% and about 0.5%, particularly at about 0.1%, at about 0.2%.
In one embodiment of the present invention, topical pharmaceutical composition may not contain any paraben.
In preferred embodiment, the preservative is potassium sorbate. In particular embodiment, potassium sorbate is the sole preservative present in the composition.
In certain embodiments of the present invention, topical pharmaceutical composition comprises humectant selected from the group consisting of sorbitol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, glycerol, mannitol, xylitol, maltitol, glycerol ethylene oxide (EO), propylene oxide (PO) adducts, and combinations thereof.
The herbal topical composition of the invention preferably are made in a gel base. Preferably, gel base comprises water, glycerine, Sepineo P600 (acetalization product between glucose and 12-hydroxystearyl alcohol - Seppic) and potassium sorbate.
Also unexpectedly, it has been found that the activity is highly prolonged with less side effects particularly when compared to popular or leading commercially available preparations.
Sample gel formulation is below:
Example 1.
Figure imgf000006_0001

Claims

Claims
1. A topical pharmaceutical composition characterized in that it comprises Calendula officinalis, Hypericum perforatum and a local anesthetic.
2. A topical pharmaceutical composition according to claim 1, wherein it comprises Calendula officinalis oil and Hypericum perforatum oil.
3. A topical pharmaceutical composition according to claim 1, wherein local anesthetic is selected from the group consisting of Benzocaine, Chloroprocaine, Cyclomethycaine, Dimethocaine, Piperocaine, Propoxycaine, Procaine, Proparacaine, Tetracaine, Articaine, Buph/acaine, Cinchocaine, Etidocaine, Levobupivacaine, Lidocaine, Mepivacaine, Prilocaine, Ropivacaine, Trimecaine and pharmaceutical acceptable salts thereof.
4. A topical pharmaceutical composition according to claim 3, wherein local anesthetic is lidocaine base or pharmaceutical acceptable salts thereof.
5. A topical pharmaceutical composition according to claim 1 , wherein it is in the form of gel.
6. A topical pharmaceutical composition according to claim 5, wherein it comprises water, glycerine, Sepineo P600 and potassium sorbate as gel base.
7. A topical pharmaceutical composition according to claim 1, wherein it does not contain any paraben.
8. A topical pharmaceutical composition according to the proceeding claims, wherein it uses for the wound healing and pain relieving.
PCT/TR2015/000088 2015-03-05 2015-03-05 A topical composition comprising calendula, hypericum and lidocaine Ceased WO2016140629A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/TR2015/000088 WO2016140629A1 (en) 2015-03-05 2015-03-05 A topical composition comprising calendula, hypericum and lidocaine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2015/000088 WO2016140629A1 (en) 2015-03-05 2015-03-05 A topical composition comprising calendula, hypericum and lidocaine

Publications (1)

Publication Number Publication Date
WO2016140629A1 true WO2016140629A1 (en) 2016-09-09

Family

ID=52824536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2015/000088 Ceased WO2016140629A1 (en) 2015-03-05 2015-03-05 A topical composition comprising calendula, hypericum and lidocaine

Country Status (1)

Country Link
WO (1) WO2016140629A1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042963A2 (en) 1996-05-10 1997-11-20 Nino Shikhashvili Green ointment
WO2005063266A1 (en) 2003-12-31 2005-07-14 Vladimir Yosifov Naydenov Therapeutical composition for the treatment of dermatosis comprising an extract of calendula officinalis and hypericum perforatum
US20090202664A1 (en) * 2008-02-11 2009-08-13 Svetislav Mikalacki Herbal cream or oil for the treatment hemorroids and wounds
CA2627021A1 (en) * 2008-04-10 2009-10-10 William G. Kalyta Combination natural source/local anesthetic/dual component penetration enhancer topical formulation useful for treating pain, itching and/or inflammation of the skin
WO2011148257A1 (en) * 2010-05-27 2011-12-01 Roberto Logi Kit of parts for treating and/or preventing cutaneous ulcers
RO128599A2 (en) * 2011-09-30 2013-07-30 Anca Irina Prisăcaru Phytotherapy wound-healing ointments
RO128713A2 (en) * 2012-01-16 2013-08-30 Andrei-Gheorghe Zbuchea Ointment with complex effects for treating burns and wounds, made exclusively of natural products
EP2735309A1 (en) * 2012-11-27 2014-05-28 Eduardo Cos Alfonso Pharmaceutical composition for the treatment of calcific tendinitis and/or calcific bursitis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042963A2 (en) 1996-05-10 1997-11-20 Nino Shikhashvili Green ointment
US5997876A (en) 1996-05-10 1999-12-07 Shikhashvili; Nino Burn and wound ointment
WO2005063266A1 (en) 2003-12-31 2005-07-14 Vladimir Yosifov Naydenov Therapeutical composition for the treatment of dermatosis comprising an extract of calendula officinalis and hypericum perforatum
US20090202664A1 (en) * 2008-02-11 2009-08-13 Svetislav Mikalacki Herbal cream or oil for the treatment hemorroids and wounds
CA2627021A1 (en) * 2008-04-10 2009-10-10 William G. Kalyta Combination natural source/local anesthetic/dual component penetration enhancer topical formulation useful for treating pain, itching and/or inflammation of the skin
WO2011148257A1 (en) * 2010-05-27 2011-12-01 Roberto Logi Kit of parts for treating and/or preventing cutaneous ulcers
RO128599A2 (en) * 2011-09-30 2013-07-30 Anca Irina Prisăcaru Phytotherapy wound-healing ointments
RO128713A2 (en) * 2012-01-16 2013-08-30 Andrei-Gheorghe Zbuchea Ointment with complex effects for treating burns and wounds, made exclusively of natural products
EP2735309A1 (en) * 2012-11-27 2014-05-28 Eduardo Cos Alfonso Pharmaceutical composition for the treatment of calcific tendinitis and/or calcific bursitis

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Glycerine - An Overview", 1990, New York, XP002744401, Retrieved from the Internet <URL:http://www.aciscience.org/docs/glycerine_-_an_overview.pdf> [retrieved on 20150911] *
ANONYMOUS: "sorbic acid and potassium sorbate as cosmetic preservatives", April 1998 (1998-04-01), XP002744403, Retrieved from the Internet <URL:http://www.lotioncrafter.com/pdf/Sorbic_Acid_and_Potassium_Sorbate.pdf> [retrieved on 20150911] *
ANOYNYMOUS: "SEPINEO P 600", 2 April 2008 (2008-04-02), XP002744402, Retrieved from the Internet <URL:http://gyermed.hu/pdf/3664_Leaflet_Sepineo_P600_gb.pdf> [retrieved on 20150911] *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; January 2013 (2013-01-01), DIXIT P ET AL: "A brief study on marigold (tagetes species): A review", XP002744404, Database accession no. EMB-2013172872 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; October 2010 (2010-10-01), MISHRA ARUN K ET AL: "Calendula officinalis: An important herb with valuable theraputic dimensions - An overview", XP002744405, Database accession no. EMB-2011150860 *
DATABASE WPI Week 201373, Derwent World Patents Index; AN 2013-M23751, XP002744400 *
DIXIT P ET AL: "A brief study on marigold (tagetes species): A review", INTERNATIONAL RESEARCH JOURNAL OF PHARMACY 2013 INTERNATIONAL RESEARCH JOURNAL OF PHARMACY IND, vol. 4, no. 1, January 2013 (2013-01-01), pages 43 - 48, ISSN: 2230-8407 *
MASHKOVSKIJ M. V.: "Medicinal Means", MEDICINE, vol. 2, 1986, pages 2.424
MISHRA ARUN K ET AL: "Calendula officinalis: An important herb with valuable theraputic dimensions - An overview", JOURNAL OF GLOBAL PHARMA TECHNOLOGY 2010 JOURNAL OF GLOBAL PHARMA TECHNOLOGY IND, vol. 2, no. 10, October 2010 (2010-10-01), pages 14 - 23, ISSN: 0975-8542 *
RIDVAN POLAT ET AL: "An ethnobotanical survey of medicinal plants in Edremit Gulf (Balikesir - Turkey)", JOURNAL OF ETHNOPHARMACOLOGY, vol. 139, no. 2, 1 January 2012 (2012-01-01), pages 626 - 641, XP055131205, ISSN: 0378-8741, DOI: 10.1016/j.jep.2011.12.004 *
S. ISHIWATARI ET AL: "Effects of methyl paraben on skin keratinocytes", JOURNAL OF APPLIED TOXICOLOGY, vol. 27, no. 1, 1 January 2007 (2007-01-01), pages 1 - 9, XP055212908, ISSN: 0260-437X, DOI: 10.1002/jat.1176 *
SAREH SAMADI ET AL: "The effect of Hypericum perforatum on the wound healing and scar of cesarean", JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE (NEW YORK, N.Y.), 1 January 2010 (2010-01-01), United States, pages 113, XP055212674, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/20064022> *
SUNTAR I P ET AL: "Investigations on the in vivo wound healing potential of Hypericum perforatum L", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER IRELAND LTD, IE, vol. 127, no. 2, 3 February 2010 (2010-02-03), pages 468 - 477, XP026853072, ISSN: 0378-8741, [retrieved on 20091013] *
WASEEM SAFDAR ET AL: "PHARMACOGNOSTICAL STUDY OF THE MEDICINAL PLANT CALENDULA OFFICINALIS L. (FAMILY COMPOSITAE)", INTERNATIONAL JOURNAL OF CELL & MOLECULAR BIOLOGY, 1 January 2010 (2010-01-01), pages 108 - 116, XP055212652, Retrieved from the Internet <URL:http://www.researchgate.net/profile/Atif_Kamal/publication/228599153_Pharmacognostical_study_of_the_medicinal_plant_Calendula_officinalis_L._(family_Compositae)/links/09e4150fe105de66f6000000.pdf?inViewer=true&disableCoverPage=true&origin=publication_detail> [retrieved on 20150910] *

Similar Documents

Publication Publication Date Title
US5266318A (en) Skin therapeutic mixture containing cold-processsed aloe vera extract, with yellow sap and aloin removed
JP2668800B2 (en) Topical treatment for skin diseases
CA2891602C (en) Composition comprising an orthosilicate and its use for tissue regeneration
EP0954278B1 (en) Pharmaceutical compositions containing kukui nut oil
EP2896396A1 (en) Herbal formulation for topical wound treatment
CN111801108A (en) topical skin care composition
CN107670027B (en) Compositions and methods for treating skin conditions
RU2358750C2 (en) Pharmaceutical compositions based on barbate lichen (usnea barbata) and common st john&#39;s wort (hypericum perforatum) and application thereof
US10596205B2 (en) Topical medicament for skin and mucosal injuries
WO2016181355A1 (en) Compositions for treating and/or preventing psoriasis, prickly heat, dermatitises, neurofibromatosis type 1 and other pathologies of the dermis, mucosae, and oral cavity
KR20110139486A (en) Skin external composition for wound healing containing honey and bee venom as active ingredients
Semkina Ointments, gels, liniments, and creams containing phytopreparations (a review)
WO2016140629A1 (en) A topical composition comprising calendula, hypericum and lidocaine
ITUB20159582A1 (en) Composition, for topical use, useful for the prevention of inflammatory and / or infectious mucosal disorders.
EP3348307B1 (en) Composition comprising carnitine, sodium cholate, sodium acetate and optionally silver for use in the treatment of psoriasis
ES2269627T3 (en) ASSOCIATION OF ARNICA, RUSCO AND MENTOL.
EP1700597B1 (en) Pharmaceutical composition containing in association ubidecarenone, dexpanthenol and chlorhexidine or a pharmaceutically acceptable salt thereof for cutaneous application
WO2021080527A1 (en) Topical pharmaceutical compositions containing difluocortolone and isoconazole
CN104784541B (en) It is a kind of to be used to remove Chinese drugs agentia of acne and preparation method thereof
CN112741863A (en) Medicine for treating skin wound and preparation method thereof
BR102021009954A2 (en) DERMOPHYTOCOSMETIC COMPOSITION BASED ON COCHLOSPERMUM REGIUM (SCHRANK) PILGER LEAF EXTRACT IN COMBINATION WITH MYRACRODRUON URUNDEUVA ALL BEARWELL EXTRACT
Edwards et al. Witch Hazel
WO2020201847A1 (en) Herbal composition for the treatment of burns
Edwards et al. Witch Hazel Hamamelis virginiana L.
WO2016133471A1 (en) A topical composition comprising mupirocin and dexpanthenol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15715876

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15715876

Country of ref document: EP

Kind code of ref document: A1